Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Anti-idiotypic
Patent
1995-09-22
1998-06-16
Feisee, Lila
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Anti-idiotypic
435327, 4353723, 5303872, 4242771, 424 937, A61K 3900, A61K 39395, C07K 1600
Patent
active
057665885
ABSTRACT:
The present invention relates to methods which utilize anti-idiotypic antibodies, or fragments thereof, for tumor immunotherapy or immunoprophylaxis. Monoclonal anti-idiotypic antibodies which recognize an idiotype present on a second antibody or on a T lymphocyte or on an immune suppressor factor which is directed against a defined tumor antigen, can be used for immunization against a tumor, for immune anti-tumor activation or inhibition of suppression, or for in vitro activation of lymphocytes to be used in adoptive immunotherapy. The anti-idiotypic antibodies, or fragments thereof, can also be used to monitor anti-antibody induction in patients undergoing passive immunization to a tumor antigen by administration of anti-tumor antibody. In another embodiment, administration of T lymphocytes which express an idiotype directed against a defined tumor antigen can be used to transfer delayed-type hypersensitivity to the tumor. In another method of the invention, the induction of anti-idiotypic antibodies in vivo by administration of anti-tumor antibody or immune cells or factors exhibiting an anti-tumor idiotype can be therapeutically valuable.
REFERENCES:
Hellstrom et al., Cancer Res. 45:2210-2218 (1985).
Flood et al., Proc. Natl. Acad. Sci. U.S.A. 77:2209-2213 (1980).
Binz et al., Int. J. Cancer 29:417-423 (1982).
Forstrom et al., Nature (London) 303:627-629 (1983).
Nepom et al., Proc. Natl. Acad. Sci. U.S.A. 81:2864-2867 (1984).
Holbeck and Nepom, J. Immunol. Methods 60:47-52 (1983).
Chapman, J. Urol. 88:518-526 (1962).
Halliday and Maluish InAssessment of Immune Status by the Leukocyte Adherence Inhibition Test, Thomson, ed., Academic, New York, pp. 1-26 (1982).
Koppi and Halliday, Cell. Immunol. 66:394-406 (1982).
Koppi and Halliday, J. Natl. Cancer Inst. 66:1089-1096 (1981).
Binz and Wigzell, J. Exp. Med. 142:197-211 (1975).
Hellstrom and Hellstrom, Adv. Cancer Res. 12:167-223 (1969).
Brawn, Int. J. Cancer 6:245-249 (1970).
Hellstrom et al., Int. J. Cancer 6:346-351 (1970).
Taranger et al., Science 176:1337-1340 (1972).
Halliday, et al., Cell. Immunol. 10:467-475 (1974).
Heberman, Ad. Cancer Res. 19:207-263 (1974).
Steele et al., J. Natl. Cancer Inst. 54:959-967 (1975).
Halliday, et al., Int. J. Cancer 16:645-658 (1975).
Thomson, Cancer Res/ 39:627-629 (1979).
Hellstrom et al., In Springer Seminars in Immunopathology: Mechanism of Host Resistance in Cancer, Baldwin, ed., Springer-Verlag, New York, pp. 127-146 (1982).
Hellstrom et al., Int. J. Cancer 29:175-180 (1982).
Hellstrom Ingegerd
Hellstrom Karl Erik
Lee Victor K.
Bansal Geetha P.
Feisee Lila
Oncogen
Poor Brian W.
Savitsky Thomas R.
LandOfFree
Tumor immunotherapy using anti-idiotypic antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tumor immunotherapy using anti-idiotypic antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumor immunotherapy using anti-idiotypic antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1721855